Online inquiry

IVTScrip™ mRNA-Human ADARB2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK14314MR)

This product GTTS-WK14314MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADARB2 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_018702.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 105
UniProt ID Q9NS39
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADARB2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK14314MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WK2001MR IVTScrip™ mRNA-Human ALDH, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALDH
GTTS-WK11203MR IVTScrip™ mRNA-Human ACACA, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACACA
GTTS-WK16001MR IVTScrip™ mRNA-Human ALDH3B1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALDH3B1
GTTS-WK20492MR IVTScrip™ mRNA-Human Aldehyde Dehydrogenase 1-A1, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Aldehyde Dehydrogenase 1-A1
GTTS-WK6215MR IVTScrip™ mRNA-Human PKC-alpha, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PKC-alpha
GTTS-WK9443MR IVTScrip™ mRNA-Human ACSBG1, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACSBG1
GTTS-WK15470MR IVTScrip™ mRNA-Human ANAPC16, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANAPC16
GTTS-WK15999MR IVTScrip™ mRNA-Human ALDH3A1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALDH3A1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW